CRISPR Therapeutics stock price drops due to convertible bond issuance

LootboxPhobia · 2026-03-10T14:29:07+00:00

CRISPR Therapeutics AG announces plans to issue $350 million convertible senior bonds, with the stock price falling 6.75%. The bonds will mature in 2031 and will be used for general corporate purposes, but specific use of funds has not been detailed.

LootboxPhobia

2026-03-10 14:29:07

Abstract generation in progress

Investing.com – CRISPR Therapeutics AG (NASDAQ:CRSP) stock fell 6.75% on Tuesday after the company announced plans to issue $350 million of convertible preferred bonds.

The gene editing company said it plans to privately place the convertible preferred bonds due 2031 to qualified institutional buyers under Rule 144A of the Securities Act. It also expects to grant initial purchasers an option to buy up to an additional $52.5 million principal amount of bonds.

These bonds will be senior unsecured debt of the company and will pay interest semiannually on March 1 and September 1 each year, with the first interest payment due on September 1, 2026. The bonds will mature on March 1, 2031, unless converted, redeemed, or repurchased earlier.

Upon conversion, the company will deliver common shares with a par value of 0.03 Swiss francs per share. The interest rate, initial conversion rate, and other terms will be determined at the pricing of the offering.

CRISPR Therapeutics stated that the net proceeds from the offering will be used for general corporate purposes. The company did not provide further details on the specific use of funds.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.